BURLINGAME, Calif.--(BUSINESS WIRE)--Nov. 2, 2016--
Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company
developing a proprietary therapeutic tissue treatment platform based on
Nano-Pulse Stimulation (NPS), will host its third quarter investor
conference call on Monday, November 14, 2016, at 4:30 p.m. EST / 1:30
p.m. PST. The company will highlight progress to date on corporate
strategies and upcoming milestones, as well as provide an update on
financial results for the quarter ended September 30, 2016.
Conference Call Details
Pulse Biosciences’ Darrin Uecker, president and CEO, and other senior
executives will host the investor conference call on November 14, 2016,
at 4:30 p.m. EST / 1:30 p.m. PST. For both "listen-only" participants
and those who wish to take part in the question and answer portion of
the call, the telephone dial-in number is (844) 494-0190 (U.S.
toll-free) or (508) 637-5580 (international) using Conference ID
4064167. Listeners will also be able to access the call via webcast
available on the Investor
Section of the company's website at www.pulsebiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a medical technology company developing a
therapeutic tissue treatment platform based on Nano-Pulse Stimulation, a
proprietary cell signaling technology. Published pre-clinical studies
have shown that a single, brief exposure of Nano-Pulse Stimulation to
target tissue stimulates a cascade of events within cells and in the
surrounding microenvironment that results in apoptosis (cell death) and
the priming of a durable adaptive immune response. Pulse Biosciences is
pursuing a variety of applications for its technology that exploits the
technology’s unique biologic effect in immuno-oncology, dermatology,
aesthetics, and veterinary medicine. More information is available at www.pulsebiosciences.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161102006495/en/
Source: Pulse Biosciences, Inc.
Pulse Biosciences, Inc.
Investors:
Darrin Uecker, President
and Chief Executive Officer
IR@pulsebiosciences.com
or
Media:
Sam
Brown, Inc.
Hannah Hurdle, 818-456-4099
hannahhurdle@sambrown.com
